On Monday, AstraZeneca Plc AZN shared detailed results from the HICKORY Phase 3 trial of efzimfotase alfa (ALXN1850) for ...
Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for ...
Clinical Trials Arena on MSN
AstraZeneca pins bone disease drug’s Phase III failure on high placebo response
Despite the primary endpoint miss, AstraZeneca hopes to bring efzimfotase alfa to patients with hypophosphatasia.
AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...
Citi has maintained its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) with a target price of £186, arguing that ...
Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; ...
Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.
The investment is expected to increase the pharma giant's workforce in Massachusetts to 3,000 employees within a few years.
AstraZeneca is investing $2 billion in Miami-based Summit Therapeutics as the pharmaceutical giant deepens its relationship ...
AstraZeneca Philippines and Hi-Precision Diagnostics Center Inc. signed a memorandum of understanding to advance digital and computational pathology in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results